CURIS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CURIS, INC. (CRIS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- CURIS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- CURIS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.13, a 73.11% decline year-over-year.
- CURIS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $11.64, a 1562.86% increase year-over-year.
- CURIS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.70, a 78.19% decline year-over-year.
- CURIS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $2.96, a 74.01% decline from fiscal 2024.
- CURIS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $11.39, a 18.06% decline from fiscal 2023.
- CURIS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $13.90, a 430.53% increase from fiscal 2022.
- CURIS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.62, a 71.11% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $2.96 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | $3.04 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $3.04 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | $3.13 10-Q · filed 2025-05-06 | ||||
| 2024-12-31 | $11.39 10-K · filed 2025-03-31 | ||||
| 2024-09-30 | $11.39 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $11.65 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | $11.64 10-Q · filed 2024-05-07 | ||||
| 2023-12-31 | $13.90 10-K · filed 2024-02-08 | ||||
| 2023-09-30 | $14.27 10-Q · filed 2023-11-02 | ||||
| 2023-06-30 | $0.71 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $0.70 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $2.62 10-K · filed 2023-03-13 | ||||
| 2022-09-30 | $2.66 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $3.14 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $3.21 10-Q · filed 2022-05-05 | ||||
| 2021-12-31 | $9.07 10-K · filed 2022-02-24 | ||||
| 2021-09-30 | $9.21 10-Q · filed 2021-11-09 | ||||
| 2021-06-30 | $9.42 10-Q · filed 2021-08-03 | ||||
| 2021-03-31 | $9.13 10-Q · filed 2021-05-12 | ||||
| 2020-12-31 | $1.27 10-K · filed 2021-03-16 | ||||
| 2020-09-30 | $1.27 10-Q · filed 2020-11-10 | ||||
| 2020-06-30 | $1.27 10-Q · filed 2020-08-04 | ||||
| 2020-03-31 | $1.29 10-Q · filed 2020-05-12 | ||||
| 2019-12-31 | $1.30 10-K · filed 2020-03-19 | ||||
| 2019-09-30 | $1.26 10-Q · filed 2019-11-05 | ||||
| 2019-06-30 | $1.20 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | $1.15 10-Q · filed 2019-05-14 | ||||
| 2018-12-31 | $2.56 10-K · filed 2019-03-26 | ||||
| 2018-09-30 | $2.58 10-Q · filed 2018-11-01 | ||||
| 2018-06-30 | $3.19 10-Q · filed 2018-08-02 | ||||
| 2018-03-31 | $0.69 10-Q · filed 2018-05-03 | ||||
| 2017-12-31 | $2.51 10-K · filed 2018-03-08 | ||||
| 2017-09-30 | $2.51 10-Q · filed 2017-11-07 | ||||
| 2017-06-30 | $2.53 10-Q · filed 2017-08-03 | ||||
| 2017-03-31 | $2.52 10-Q · filed 2017-05-04 | ||||
| 2016-12-31 | $1.73 10-K · filed 2017-03-09 | ||||
| 2015-12-31 | $2.33 10-K · filed 2016-02-29 | ||||
| 2015-09-30 | $1.94 10-Q · filed 2015-11-09 | ||||
| 2015-06-30 | $1.94 10-Q · filed 2015-08-06 | ||||
| 2015-03-31 | $1.94 10-Q · filed 2015-05-07 | ||||
| 2014-12-31 | $2.65 10-K · filed 2015-02-24 | ||||
| 2014-09-30 | $1.75 10-Q · filed 2014-11-10 | ||||
| 2014-06-30 | $1.75 10-K · filed 2018-03-08 | $1.75 10-Q · filed 2014-08-07 | |||
| 2014-02-28 | $3.09 10-K · filed 2018-03-08 | ||||
| 2013-12-31 | $3.44 10-K · filed 2014-03-13 | ||||
| 2012-12-31 | $4.52 10-K · filed 2013-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |